EZH2 and cancer: Studies show that downregulating EZH2 activates Nuclear Receptor Coactivator 4 (NCOA4) to trigger ferroptosis in cancer and enhances antitumor immunity by promoting CD8 + T cell infiltration into tumor tissues [162].